News Releases

Media Inquiries

Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies

Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President